Novartis Ag (NVS) Non-Current Receivables (2017 - 2025)
Historic Non-Current Receivables for Novartis Ag (NVS) over the last 9 years, with Q4 2025 value amounting to $403.0 million.
- Novartis Ag's Non-Current Receivables rose 12513.97% to $403.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $403.0 million, marking a year-over-year increase of 12513.97%. This contributed to the annual value of $403.0 million for FY2025, which is 12513.97% up from last year.
- As of Q4 2025, Novartis Ag's Non-Current Receivables stood at $403.0 million, which was up 12513.97% from $179.0 million recorded in Q4 2024.
- In the past 5 years, Novartis Ag's Non-Current Receivables ranged from a high of $403.0 million in Q4 2025 and a low of $179.0 million during Q4 2024
- Over the past 5 years, Novartis Ag's median Non-Current Receivables value was $197.0 million (recorded in 2022), while the average stood at $235.4 million.
- In the last 5 years, Novartis Ag's Non-Current Receivables tumbled by 1635.51% in 2024 and then soared by 12513.97% in 2025.
- Over the past 5 years, Novartis Ag's Non-Current Receivables (Quarter) stood at $184.0 million in 2021, then rose by 7.07% to $197.0 million in 2022, then increased by 8.63% to $214.0 million in 2023, then dropped by 16.36% to $179.0 million in 2024, then surged by 125.14% to $403.0 million in 2025.
- Its Non-Current Receivables stands at $403.0 million for Q4 2025, versus $179.0 million for Q4 2024 and $214.0 million for Q4 2023.